Advancements in Cancer Immunotherapy: A Comprehensive Review of Immune Checkpoint Inhibitors with a Focus on Pembrolizumab and Emerging Strategies

The introduction of immune checkpoint inhibitors (ICIs) has marked a significant breakthrough in oncology, fundamentally altering cancer treatment paradigms. This review examines the transformative impact of ICIs, including PD-1 inhibitors (Nivolumab, Pembrolizumab, Cemiplimab), PD-L1 inhibitors (Atezolizumab, Durvalumab, Avelumab), and CTLA-4 inhibitors (Ipilimumab), all of which have received FDA approval for various malignancies. These agents enhance survival outcomes by reactivating the immune system to target cancer cells. Focused particularly on Pembrolizumab, a prominent PD-1 inhibitor, the review details its mechanism of action, which involves blocking the PD-1/PD-L1 interaction to restore T-cell activity against tumors. Pembrolizumab's efficacy is highlighted through clinical trials in non-small cell lung cancer, melanoma, and other cancers, demonstrating its broad-spectrum efficacy and safety profile. Predictors of response, such as PD-L1 expression and tumor mutational burden, are discussed alongside the associated immune-related adverse events (irAEs) and their management. Future directions include refining patient selection criteria, improving irAE management, and leveraging computational algorithms for personalized therapy. Emerging research on fecal microbiota transplantation (FMT) suggests the potential for enhancing ICI efficacy and managing side effects. Continued innovation and research are crucial for optimizing ICI therapy and addressing existing challenges to fully realize their potential in cancer treatment.

Keywords: Immune checkpoint inhibitors; Fecal microbiota transplantation; Autoimmunity 

Introduction
The advent of immune checkpoint inhibitors (ICIs) has significantly transformed the treatment landscape of various cancers. This class of drugs, comprising PD-1 inhibitors (Nivolumab, Pembrolizumab, Cemiplimab), PD-L1 inhibitors (Atezolizumab, Durvalumab, Avelumab), and CTLA-4 inhibitors (Ipilimumab), has been approved by the US Food and Drug Administration (FDA) for several types of cancer. ICIs have demonstrated remarkable efficacy in improving survival outcomes for patients with advanced and metastatic cancers by stimulating the immune system to recognize and destroy cancer cells. This review explores the mechanisms of action, clinical applications, predictors of response, side effects, management strategies, and future directions of ICIs, with a particular focus on Pembrolizumab, a notable PD-1 inhibitor¹.   

Mechanism of action
Immune Checkpoints and Their Role
Immune checkpoints are essential components of the immune system that help maintain self-tolerance and prevent autoimmunity. These checkpoints are regulatory pathways that modulate the immune response to ensure it is appropriately targeted and not overly aggressive. They primarily function through interactions between immune checkpoint receptors on T-cells and their corresponding ligands on antigen-presenting cells or tumor cells.

Two key immune checkpoint pathways relevant to cancer therapy are the PD-1/PD-L1 and CTLA-4 pathways:  

1. PD-1/PD-L1 Pathway:  
· PD-1 (Programmed Cell Death Protein 1): A receptor expressed on the surface of T-cells.  
· PD-L1 (Programmed Death-Ligand 1): A ligand that binds to PD-1, expressed on tumor cells and antigen-presenting cells.  
· PD-L2 (Programmed Death-Ligand 2): Another ligand for PD-1, found on some antigen-presenting cells.  

Under normal circumstances, the interaction between PD-1 and PD-L1/Pd-L2 acts as a brake on T-cell activity, reducing immune responses and promoting tolerance. This mechanism helps prevent autoimmunity by inhibiting excessive immune reactions against self-antigens.

2. CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4):  
· CTLA-4: A receptor expressed on T-cells that competes with the costimulatory receptor CD28 for binding to B7 molecules (CD80/CD86) on antigen-presenting cells. 
· CD80/CD86: Ligands on antigen-presenting cells that provide necessary signals for T-cell activation.   

CTLA-4 engagement with CD80/CD86 inhibits T-cell activation and promotes T-cell exhaustion, contributing to immune evasion by tumors².   

Mechanism of Action of Pembrolizumab   
Pembrolizumab is a humanized monoclonal antibody that specifically targets PD-1. The detailed mechanism of action is as follows:  

1. Binding to PD-1:
• Pembrolizumab binds with high affinity to PD-1 receptors on T-cells, thereby blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 (Figure 1).
• This inhibition prevents the PD-1/PD-L1 and PD-1/PD-L2 interactions, which are crucial for downregulating T-cell responses.

2. Reactivation of T-Cells:
• By blocking PD-1, Pembrolizumab removes the inhibitory signals that would otherwise dampen T-cell activity.
• This reactivation of T-cells enhances their ability to recognize and attack tumor cells, effectively boosting the anti-tumor immune response.

3. Lack of Direct Cytotoxic Effects:
• Unlike cytotoxic antibodies that directly kill target cells through mechanisms like complement activation or engagement of Fc receptors, Pembrolizumab does not induce direct cell death.
• It operates through immunomodulation rather than cytotoxicity, altering the immune environment to enhance T-cell-mediated tumor destruction.

4. Effective Inhibitory Concentration:  
· The 50% effective inhibitory concentration (IC50) of Pembrolizumab in T-cell activation assays, which measures its potency, ranges from 0.1 to 0.3 nM. This indicates its strong efficacy in blocking the PD-1 pathway and reactivating T-cells²  

In summary, Pembrolizumab functions by blocking the PD-1 receptor on T-cells, thereby disrupting the inhibitory signals that tumors use to evade immune surveillance. This action restores and enhances T-cell activity against cancer cells, making it a powerful tool in cancer immunotherapy.


Figure 1: Mechanism of action of pembrolizumab

Clinical applications
Non-Small Cell Lung Cancer (NSCLC)
Survival Advantage and Clinical Trials: Pembrolizumab has significantly altered the treatment landscape for advanced NSCLC, particularly in patients with high PD-L1 expression. The KEYNOTE-024 trial, a landmark study, evaluated Pembrolizumab as a first-line treatment for patients with NSCLC and a PD-L1 tumor proportion score (TPS) of 50% or greater.  
· KEYNOTE-024 Trial Findings: The trial demonstrated that Pembrolizumab provided a substantial survival benefit compared to platinum-based chemotherapy. Patients treated with Pembrolizumab had a median overall survival (OS) of 20.0 months versus 12.2 months for those receiving chemotherapy. Furthermore, Pembrolizumab was associated with a higher progression-free survival (PFS) rate, highlighting its effectiveness as a first-line therapy³.   
· Adverse Events: The trial also revealed a favorable safety profile for Pembrolizumab compared to chemotherapy. Pembrolizumab resulted in fewer severe treatment-related adverse events (31.2%) compared to chemotherapy (53.3%), underscoring its relative safety advantage³.  

Melanoma
The KEYNOTE-001 trial assessed Pembrolizumab, a PD-1 inhibitor, in advanced melanoma patients. It demonstrated:
• Sustained Effectiveness: Pembrolizumab provided durable tumor responses over five years, with high objective response rates in both treatment-naive and previously treated patients.
• Safety Profile: The drug maintained a favorable safety profile with manageable immune-related adverse events and comparable or improved quality of life outcomes. 
· Clinical Implications: Effective as both a first-line and subsequent treatment, Pembrolizumab showed long-term benefit and flexibility in managing advanced melanoma⁴

Real-World Data: Real-world studies further supported the trial findings:
• Durability of Response: Pembrolizumab offered long-lasting responses similar to trial results, with benefits extending across various patient populations.
• Clinical Outcomes: Enhanced overall survival and improved quality of life in clinical practice were reported. 
· Safety and Tolerability: Consistent with trial data, the safety profile was favorable, confirming Pembrolizumab's role as a long-term therapeutic option⁵